iQure Pharma .iQure Pharma .
iQure Pharma .

iQure Pharma .

Restores glutamate homeostasis by targeting astrocyte biology, breaking the cycle of excitotoxicity across CNS diseases.

Website
2017Active9
Advertise here
About
iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics to restore glutamate balance in CNS disorders. Their lead asset, iQ-007, is an orally available EAAT2 positive allosteric modulator designed to enhance glutamate uptake and break the cycle of excitotoxicity. The company is initially focusing on epilepsy as a clinical validation path, with Parkinson's disease, migraine, and ALS as additional opportunities.

Technology stack

detected 2026-06-04
Est. monthly stack spend~$170/mo
Emailunknown
Hosting
self_managed
Stack
jQuery
Analytics
Google Analytics 4
Performance

Company Timeline

Frequently asked

What does iQure Pharma . do?

iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics to restore glutamate balance in CNS disorders. Their lead asset, iQ-007, is an orally available EAAT2 positive allosteric modulator designed to enhance glutamate uptake and break the cycle of excitotoxicity. The company is initially focusing on epilepsy as a clinical validation path, with Parkinson's disease, migraine, and ALS as additional opportunities.

How much funding has iQure Pharma . raised?

iQure Pharma . has raised a total of $10M in funding. The most recent round on record is Seed.

Where is iQure Pharma . headquartered?

iQure Pharma . is headquartered in Cambridge, United States.

When was iQure Pharma . founded?

iQure Pharma . was founded in 2017.

What industry does iQure Pharma . operate in?

iQure Pharma . operates in Biotech, HealthTech, Drug Discovery, Neuroscience, CNS Diseases, Astrocyte Biology.

How many employees does iQure Pharma . have?

iQure Pharma . has approximately 9 people on record.